PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 1, 1994Catheterization and Cardiovascular Diagnosis

Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does a regimen of ticlopidine and subcutaneous heparin prevent subacute thrombosis in patients undergoing coronary stenting?

Population

238 patients with placement of one or more stents in 244 arteries

Design

Cohort

Follow-up

30 days

Authors

PBPaul BarraganJSJoël SainsousMSMarc Silvestri

Discussion

Loading...

Member takes

Overview

A regimen of ticlopidine and subcutaneous heparin following coronary stenting resulted in a 30-day subacute thrombosis rate of 4.2%, with age <70, unstable angina, and vessel diameter <3mm identified as predictive factors for thrombosis.

Structured PICO

Does a regimen of ticlopidine and subcutaneous heparin prevent subacute thrombosis in patients undergoing coronary stenting?

P
Population
238 patients with placement of one or more stents in 244 arteries
I
Intervention
Ticlopidine 500 mg/day (started 3 days before procedure and continued for 3-6 months) and heparin (10,000 IU push during procedure, 1,000-1,500 IU/hr for 20 hr, then subcutaneous for 1 week)
O
Outcome
Subacute thrombosis of coronary stents at 30 dayshard clinical

A regimen of ticlopidine and subcutaneous heparin following coronary stenting resulted in a 30-day subacute thrombosis rate of 4.2%, with age <70, unstable angina, and vessel diameter <3mm identified as predictive factors for thrombosis.

Cite This Study

Barragan et al. (1994) studied this question.

synapsesocial.com/papers/6a737a548317ef39e84e606bhttps://doi.org/10.1002/ccd.1810320208
View Full Paper
Ask AI
Bookmark
Share